Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2007)
13 slides from Resonance Health's shareholder meeting presentation, Nov 20, 2007
Slide 1: Annual General Meeting
For personal use only Resonance Health Limited Resonance Health Limited ACN 006 762 492 Annual General Meeting Annual 20 NovemberGeneral 2007 Meeting 20 November 2007
Slide 2: Agenda
For personal use only Agenda Milestones FerriScan® Market Strategy Financial Performance Conclusion
Slide 3: Milestones
For personal use only Milestones 2005 Regulatory Clearance in Australia Regulatory Clearance in Europe Regulatory Clearance in USA 2006 ISO 9001 and 13485 accreditation Regulatory Clearance in Canada Regulatory Clearance in NZ Contract signed with Genzyme Pharmaceuticals 2007 Successful ISO and Heal
Slide 4: FerriScan Availability
For personal use only FerriScan Availability 100 MRI scanners set up for FerriScan – Increased from 56 in June 2006 20 Countries – Australia/NZ – Nth America – USA, Canada – Asia – Malaysia, HK, India, Singapore, Korea – EU – UK, Germany, Italy, Greece, Spain, Denmark – Middle East – Turkey, Egypt,
Slide 5: FerriScan Market – Iron Overload
For personal use only FerriScan Market – Iron Overload Primary Iron Overload – Hereditary haemochromatosis -1 in 200 in population from Nth EU descent – Excessive dietary iron absorption Transfusional Iron Overload – Thalassaemia – 100,000 new severe cases each year – Sickle Cell Anaemia - 20,000 tr
Slide 6: Thalassaemia
For personal use only Thalassaemia Affects over 1 million people worldwide Excess iron accumulates as a result of repeated blood transfusions Chelation therapy introduces a drug that binds to the excess iron to aids its excretion FerriScan provides an accurate measure of iron levels for drug dose ma
Slide 7: Clinical Applications of FerriScan
For personal use only Clinical Applications of FerriScan When to initiate, increase or decrease chelation therapy Used to confirm ambiguous diagnosis of hereditary haemochromatosis Used to assess organ damage risks associated with high liver iron levels
Slide 8: Reimbursement
For personal use only Reimbursement No. 1 issues for wide spread clinical use of FerriScan AUS, UK, Italy, Germany – 10,000 transfusion dependent patients – $2 million pa potential revenue Sickle Cell in the USA – 20,000 transfusion dependent patients – $4 million pa potential revenue Australian sub
Slide 9: FibroScreen
For personal use only FibroScreen MedPharma Report – Large Market - 5m people with Hepatitis worldwide – Some Fibrosis tests are available, but lack accuracy Next Steps – Further R&D to improve sensitivity of test – Opportunity - Fatty Liver – 40m people in USA – Collaborations
Slide 10: Strategy
For personal use only Strategy Current Position: – New fee structure and long term relationship planned with Novartis – Cash flow positive outlook to mid 2008 Gain medical insurance reimbursement for FerriScan Maintain cash reserves until reimbursement achieved Gain acceptance with clinical opinion
Slide 11: Financial Performance
For personal use only Financial Performance Cash balance remains strong following capital raising in September 2006 Cash balance at 19 Nov is $1,983,664 Improving revenue trend Restructure of Board and US office closure (post 30 June 2007) Continuing focus on increasing revenue and managing costs
Slide 12: Financial Information
For personal use only Financial Information 30 June 2007 2006 2005 Revenue $2.1m $0.6m $0.3m Net Loss after Tax -$0.7m -$16.0m* -$1.9m # shares on issue 375.0m 204.6m 201.5m Cash on Hand $2.4m $0.6m $1.5m * Includes impairment of goodwill on consolidation
Slide 13: Conclusion
For personal use only Conclusion Re-pricing of FerriScan achieved Long term contract with Novartis achieved Significant reduction in operating expenses achieved Reimbursement strategy continuing Company well positioned for growth and synergistic expansion
Resonance Health — Shareholder Meeting (November 2007) on 6ix